The FDA granted 510(k) clearance for the 790 laser for performing titanium-sapphire laser trabeculoplasty by Solx, Inc., Waltham, Mass. The device reduces intraocular pressure (IOP) in patients with primary open angle glaucoma and poorly controlled IOP on maximally tolerated medications or prior failed trabeculoplasty. The laser emits pulses of energy to loosen particles in the trabecular meshwork without causing significant thermal damage. The energy penetrates deeper into the tissue than other trabeculoplasty lasers, which may lead to longer lasting benefits, according to Solx.